Q4 2019

Filed Mar 5, 2020 · 10-K · 65 days after period end · 0001564590-20-009016

Q4 2019 · 10-K

Revenue

$380.00K

±0.0% vs Q4 2018

Net Income

-$14.00M

N/M vs Q4 2018

EPS Diluted

-$0.44

N/M vs Q4 2018

Operating Income-$14,205,000N/M

Operating Cash Flow

Same quarter

Metric	Q4 2019	Q4 2018	Q4 2017	Q4 2016
Revenue	$380.00K	$380.00K	$1.19M	$305.00K
Net Income	-$14.00M	-$18.84M	-$19.10M	-$10.82M
EPS Diluted	-$0.44	$0.70	-$0.80	-$0.59

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR